<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Marburg virus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Marburg virus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Marburg virus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mike Bray, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel S Chertow, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H464349628"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The family <em>Filoviridae </em>consists of three genera: <em>Ebolavirus </em>and <em>Marburgvirus</em>, which are among the most virulent pathogens of humans [<a href="#rid1">1-3</a>], and <em>Cuevavirus, </em>which has only been detected in bats in Spain [<a href="#rid3">3,4</a>]. Marburg virus caused the first recognized epidemics of filovirus disease in humans, when infected nonhuman primates were inadvertently imported from Uganda into Germany and Yugoslavia in 1967 [<a href="#rid5">5,6</a>]. Since then, the virus has caused several outbreaks across Sub-Saharan Africa [<a href="#rid7">7</a>]. A single fatal case of Marburg virus disease was detected in Guinea in August 2021, and two fatal cases were detected in Ghana in July 2022 [<a href="#rid8">8</a>]. In April 2023, outbreaks in Equatorial Guinea and Tanzania were reported [<a href="#rid9">9</a>]. Reliable information on filovirus outbreaks can be obtained from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fhealth-topics%2Fmarburg-virus-disease%2F&amp;token=orMeNG1S9%2BGAx7wBzvCzMYntEZ5n03JqoY7JPtr1ouWaOpcLyDOVrALrKNayupa3FAuf%2FHbbuVWKnTlRUDjA2Q%3D%3D&amp;TOPIC_ID=98084" target="_blank">World Health Organization website</a>.</p><p>Similar to Ebola virus, Marburg virus causes a rapidly progressive febrile illness that leads to shock and death in a large proportion of infected individuals. Bleeding is observed in some patients, and the disease has traditionally been labeled "Marburg hemorrhagic fever" [<a href="#rid10">10</a>]. However, few patients develop significant hemorrhage, and it is rarely the cause of death. Thus, the syndrome caused by Marburg virus is now designated "Marburg virus disease," just as the term "Ebola hemorrhagic fever" has been replaced by "Ebola virus disease." Because of the biological differences between filovirus genera, vaccines and specific therapies that have been developed against Ebola virus disease will not be effective against Marburg.</p><p>This topic reviews the epidemiology, clinical manifestations, treatment, and other aspects of the disease caused by members of the genus <em>Marburgvirus</em>. Detailed discussions of Ebola virus disease are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3023.html" rel="external">"Epidemiology and pathogenesis of Ebola virus disease"</a> and  <a class="medical medical_review" href="/z/d/html/3022.html" rel="external">"Clinical manifestations and diagnosis of Ebola virus disease"</a> and  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease"</a>.)</p><p class="headingAnchor" id="H464349866"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The filoviruses are nonsegmented, negative-sense, single-stranded RNA viruses. The family name is derived from the Latin "filum," meaning "thread-like," based upon the filamentous structure of the virion. The filoviruses resemble rhabdoviruses and paramyxoviruses in their genome organization and intracellular replication mechanism. (See  <a class="medical medical_review" href="/z/d/html/8322.html" rel="external">"Clinical manifestations and diagnosis of rabies", section on 'Virology'</a> and  <a class="medical medical_review" href="/z/d/html/3019.html" rel="external">"Measles: Epidemiology and transmission"</a>.)</p><p>The genus <em>Marburgvirus</em> contains a single species that consists of two recognized variants, <em>Lake Victoria marburgvirus</em> and <em>Ravn marburgvirus</em>, which show approximately 20 percent overall sequence divergence [<a href="#rid10">10,11</a>]. The Ravn variant was responsible for a single case in South Africa in 1987 and for some of the infections among miners exposed to bats in the eastern Democratic Republic of the Congo; all other human cases, including the case in Guinea that occurred in 2021, have been caused by the Lake Victoria variant [<a href="#rid12">12,13</a>]. (See <a class="local">'Epidemiology'</a> below.)</p><p>Both variants of Marburg virus apparently cause similar diseases in humans and certain laboratory animals. In addition, nonhuman primates that have received an experimental vaccine based on one variant are cross-protected against the other [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H464354381"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H709225079"><span class="h2">Endemic areas</span><span class="headingEndMark"> — </span>The first recognized outbreak of Marburg virus disease occurred at separate sites in Germany and Yugoslavia in 1967; the overall fatality rate was 23 percent [<a href="#rid5">5,6</a>]. Both outbreaks were a result of the inadvertent importation of infected vervet monkeys (<em>Chlorocebus pygerythrus</em>) from Uganda for use in vaccine production. Subsequent field studies of trapped animals in Uganda and adjacent countries failed to identify a viral reservoir host.</p><p>Since 1967, all known human infections with Marburg virus have occurred in Africa [<a href="#rid12">12,16,17</a>]. Fatality rates among patients have been as high as 80 to 90 percent [<a href="#rid7">7,10</a>]. Reports of Marburg virus disease include:</p><p class="bulletIndent1"><span class="glyph">●</span>In 1975, a young man who had been hitchhiking in Rhodesia became ill after arriving in South Africa; the infection spread to a travelling companion and to a nurse who cared for them [<a href="#rid18">18</a>]. The source was not identified. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The next recognized outbreak did not take place until 1998, when cases of severe febrile illness were seen among men working in an abandoned mine in the eastern part of the Democratic Republic of the Congo (DRC), where they were heavily exposed to bats and bat excretions [<a href="#rid12">12</a>]. Genomic analysis of virus isolates obtained over the course of the epidemic revealed that miners had been infected with multiple virus variants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The largest epidemic, with more than 250 confirmed cases, occurred in Angola in 2004 and centered on a pediatric ward where infection was apparently spread through the use of contaminated transfusion equipment. In contrast to the outbreak in Uganda described above, genomic analysis found that only a single introduction of virus had occurred [<a href="#rid11">11</a>]. The source of infection was not identified. Two reports provide a detailed description of the response of the international organization Médecins Sans Frontières to the Angola epidemic [<a href="#rid19">19,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since 2004, Marburg virus disease has been identified primarily in Uganda. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In 2009, two cases occurred separately in tourists who had entered the same bat-infested cave. One was a Dutch woman who was "bumped" by a bat during a visit to the cave; upon returning home, she developed a rapidly progressive illness, leading to her death [<a href="#rid21">21</a>]. News of the case resulted in the retrospective identification of a nonfatal illness in a woman from Colorado who had visited the same cave in 2008 and subsequently developed a febrile illness with hepatitis, coagulopathy, and encephalopathy [<a href="#rid22">22</a>]. Screening of her serum revealed antibodies to Marburg virus.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In 2012, cases of Marburg virus disease were identified in four different locations in Uganda [<a href="#rid23">23</a>]. All chains of transmission originated from a single source, with amplification through attendance at a traditional funeral. No history of exposure to bats or other potential reservoir species was obtained. The outbreak was contained within two weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In October 2017, a small outbreak occurred in Uganda; the index case was attributed to exposure to bats during rock salt mining [<a href="#rid24">24</a>]. Four members of one family became infected, of whom three died. Surveillance of more than 300 potential contacts found no additional cases [<a href="#rid25">25</a>]. The outbreak was declared over in mid-December 2017. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In August 2021, the first case of Marburg virus disease in West Africa was diagnosed in an individual who died after suffering major hemorrhages in the Guéckédou Prefecture in the Nzérékoré Region of southwestern Guinea [<a href="#rid8">8,26</a>]. The patient was diagnosed with Marburg virus disease post-mortem. Careful monitoring found no secondary cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In July 2022, an outbreak was recognized in Ghana [<a href="#rid27">27</a>]. A 26-year-old man presented with fever, vomiting, diarrhea, and epistaxis, and the diagnosis of Marburg virus disease was made at the Noguchi Memorial Institute for Medical Research. The man's wife and infant child also became infected; only the wife survived.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2023, two outbreaks of Marburg virus disease were reported, one in Equatorial Guinea and one in Tanzania [<a href="#rid9">9</a>]. Sequencing of virus isolates did not indicate any connection between these outbreaks, which are occurred on opposite sides of the continent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Equatorial Guinea – An outbreak of Marburg virus disease was confirmed in Equatorial Guinea on February 12, 2023 and was declared over on May 15, 2023 [<a href="#rid28">28-31</a>]. During this outbreak there were 17 laboratory-confirmed cases, of which 12 were fatal [<a href="#rid30">30,32</a>]. Twenty-three probable cases were also reported, and all of those patients died.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tanzania – On March 21, 2023 the Ministry of Health of Tanzania announced the first outbreak of Marburg virus disease in the country; the outbreak was declared over on June 2, 2023 [<a href="#rid33">33</a>]. The outbreak occurred in the northwest Kagera region [<a href="#rid9">9</a>]. There were eight laboratory-confirmed cases and one probable case; six were fatal [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H464350014"><span class="h2">Viral reservoirs</span><span class="headingEndMark"> — </span>In 2009, scientists at the United States Centers for Disease Control and Prevention succeeded in recovering infectious Marburg virus from Egyptian fruit bats (<em>Rousettus aegyptiacus</em>) captured in a mine in Uganda where numerous cases had occurred over a 10-year period [<a href="#rid12">12</a>]. The isolates showed considerable genomic variation, suggesting that the virus had been present in the bat population for a long time, permitting significant diversification. Studies in captive <em>R. aegyptiacus</em> have found that chronically infected animals shed virus in oral and vaginal fluids without becoming ill, and that increased shedding occurs when female bats give birth [<a href="#rid34">34-36</a>]. </p><p>The wide geographic dispersion of cases of Marburg virus disease in South Africa, Uganda, the DRC, Angola, and Guinea, as listed above, suggests that the virus is present among chronically infected bats throughout much of sub-Saharan Africa [<a href="#rid37">37-39</a>]. In 2020, this was confirmed by the recovery of infectious virus from apparently healthy cave-dwelling fruit bats in Sierra Leone [<a href="#rid40">40</a>]. The virus sequence closely resembled that which caused the Angola epidemic in 2004. </p><p>In addition to the recovery of infectious virus, Marburg virus RNA has been detected in rectal swabs of <em>R. aegyptiacus</em> bats in caves in South Africa and in Zambia [<a href="#rid41">41,42</a>]. Laboratory studies of captive fruit bats experimentally infected with Marburg or Ebola virus have found that tolerance of infection results from the upregulation of protective interferon-stimulated antiviral genes, while proinflammatory responses are dampened [<a href="#rid43">43,44</a>].</p><p>Further evidence of a role of bat exposure is provided by a serologic survey in Uganda, which found that miners were more than five times more likely to have antibodies against Marburg virus in their serum than a control group in a non-mining area of the country [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H464353560"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>Marburg virus spreads from person to person by the same mechanisms as Ebola virus, through direct contact with the blood or other body fluids of a patient or during preparation of a body for burial. As an example, treatment of the 25 patients during the outbreak in Germany and Yugoslavia resulted in 6 secondary infections among doctors and nurses [<a href="#rid5">5</a>]. </p><p>Infection during patient care or washing of a cadaver may result from the inadvertent transfer of virus on contaminated hands to the mouth or eyes. When appropriate precautions have been used, secondary spread has been limited [<a href="#rid5">5,18</a>]. In contrast, if clinicians do not suspect the diagnosis and/or are not able to employ adequate infection control measures, the spread of virus may be enhanced. As an example, Marburg virus appears to have been transmitted through improperly sterilized injection equipment during the 2004 outbreak in Angola [<a href="#rid46">46</a>]. Infection prevention and control precautions used to care for patients with Marburg virus should be the same as those employed to care for those with Ebola virus disease. (See  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease", section on 'Infection control precautions during acute illness'</a>.) </p><p>Infection may also be transmitted in the semen of men who have recovered from Marburg virus disease. In the 1967 outbreak in Germany, a man who survived infection transmitted the virus to his wife after discharge from the hospital, apparently through sexual intercourse. A laboratory study of male nonhuman primates who survived acute Marburg virus infection revealed persistence of virus in the testes [<a href="#rid47">47</a>]. This is similar to transmission of Ebola virus. (See  <a class="medical medical_review" href="/z/d/html/3022.html" rel="external">"Clinical manifestations and diagnosis of Ebola virus disease", section on 'Convalescence'</a>.)</p><p>There are no data to suggest that Marburg virus is transmitted among humans by mosquitoes or other biting arthropods. In addition, although laboratory animals have been infected by exposure to aerosolized virus [<a href="#rid48">48</a>], there is no evidence that patients with Marburg virus disease have transmitted the infection to others by the respiratory route. </p><p class="headingAnchor" id="H464351738"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of Marburg virus disease closely resembles that of Ebola virus disease [<a href="#rid49">49-51</a>]. (See  <a class="medical medical_review" href="/z/d/html/3023.html" rel="external">"Epidemiology and pathogenesis of Ebola virus disease"</a>.)</p><p>After the virus enters the body via mucous membrane or skin penetration, macrophages and dendritic cells are the first cells to be infected. Filoviruses replicate readily within these ubiquitous "sentinel" cells, causing their necrosis and releasing large numbers of new viral particles into extracellular fluid  (<a class="graphic graphic_figure graphicRef57590" href="/z/d/graphic/57590.html" rel="external">figure 1</a>). The spread of virus via lymphatic channels to regional lymph nodes results in further rounds of replication, followed by bloodstream dissemination to dendritic cells and to fixed and mobile macrophages in the liver, spleen, and other lymphoid tissues. Two virus-encoded proteins, VP24 and VP35, facilitate rapid systemic dissemination by blocking the production of type I interferon by infected cells and inhibiting the response to exogenous interferon [<a href="#rid52">52</a>]. Further spread of virus to hepatocytes, adrenal cortical, and other parenchymal cells results in extensive tissue necrosis [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H464351821"><span class="h2">Systemic inflammatory response</span><span class="headingEndMark"> — </span>As in Ebola virus disease, systemic inflammation plays a critical role in the etiology of vascular dysfunction, shock, and death from Marburg virus disease. Infected macrophages and other target cells produce large quantities of proinflammatory cytokines and chemokines, while the release of nitric oxide, prostacyclin, and other vasoactive substances produces a general increase in vascular permeability [<a href="#rid49">49,53</a>]. In addition to the effects of circulating proinflammatory mediators, the production of tissue factor on the surface of virus-infected cells triggers coagulation cascades, leading to disseminated intravascular coagulation [<a href="#rid54">54,55</a>]. </p><p class="headingAnchor" id="H464351995"><span class="h2">Impairment of adaptive immunity</span><span class="headingEndMark"> — </span>Patients dying of filovirus disease typically fail to show an antibody response to the virus [<a href="#rid56">56</a>]; this impairment reflects both direct and indirect attacks on immune function. Dendritic cells, which have primary responsibility for the initiation of adaptive immune responses, fail to be activated by filoviral infection and are destroyed through necrosis [<a href="#rid57">57</a>]. Adaptive immunity is also impaired by a massive loss of lymphocytes. These cells are not infected by filoviruses but undergo "bystander" apoptosis, presumably induced by inflammatory mediators and/or the loss of support signals from dendritic cells [<a href="#rid58">58</a>]. </p><p class="headingAnchor" id="H464352219"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Marburg virus causes a rapidly progressive febrile illness that leads to shock and death in a large proportion of infected individuals [<a href="#rid7">7,59</a>]. The clinical manifestations and laboratory findings seen in patients with Marburg virus disease are similar to those produced by Ebola virus (see  <a class="medical medical_review" href="/z/d/html/3022.html" rel="external">"Clinical manifestations and diagnosis of Ebola virus disease", section on 'Clinical manifestations'</a>). These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Following an incubation period averaging one week, Marburg virus disease typically begins with the abrupt onset of fever, chills, and general malaise [<a href="#rid10">10,60</a>]. Other signs and symptoms may include weakness, anorexia, severe headache, and pain in the muscles of the trunk and lower back. Vomiting and diarrhea may lead to acute, severe fluid loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding is rare in the early phase of illness but may become manifest later in the form of petechial hemorrhages of mucous membranes, ecchymoses, and continued oozing from venipuncture sites. Significant bleeding from the gastrointestinal tract or other sites is usually observed only during the terminal phase of fatal infections. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional clinical findings may include a diffuse maculopapular rash, hiccups, chest pain, shortness of breath, headache, confusion, seizures, obtundation, and coma. </p><p></p><p>Abnormalities in clinical laboratory tests include leukopenia, thrombocytopenia, elevations in serum transaminase (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) levels, increases in serum blood urea nitrogen (BUN) and creatinine, and abnormal coagulation indices [<a href="#rid10">10</a>]. As an example, in the 1967 Marburg outbreak, many patients had striking leukopenia, with total white blood cell counts as low as 1000/microL, and immature forms at the time of clinical presentation [<a href="#rid5">5</a>]. Serum aminotransferase levels rose rapidly on days 6 to 8 of illness and became highest in patients who died from infection. (See  <a class="medical medical_review" href="/z/d/html/3022.html" rel="external">"Clinical manifestations and diagnosis of Ebola virus disease", section on 'Laboratory findings'</a>.) </p><p class="headingAnchor" id="H464349656"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of Marburg virus disease is based upon the detection of specific RNA sequences by reverse-transcription polymerase chain reaction (RT-PCR) or viral antigens by enzyme-linked immunosorbent assay (ELISA). However, in contrast to Ebola virus disease, for which rapid diagnostic tests underwent field testing during the West African epidemic [<a href="#rid61">61</a>], rapid tests for Marburg virus are still confined to the research laboratory. A discussion of the tests used to diagnose Ebola virus disease is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3022.html" rel="external">"Clinical manifestations and diagnosis of Ebola virus disease", section on 'Diagnostic tests'</a>.)</p><p class="headingAnchor" id="H464349663"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Management of Marburg virus disease relies on aggressive supportive care to prevent the development of shock while the patient's immune system mobilizes the responses needed to eliminate the virus. The approach to supportive care as well as infection prevention and control precautions used when caring for patients with Marburg virus are similar to those employed to care for patients with Ebola virus disease. (See  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease", section on 'Supportive care'</a> and  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease", section on 'Infection control precautions during acute illness'</a>.) </p><p>There are no approved specific treatments for Marburg virus disease. Although antiviral therapies have been approved for treatment of Ebola virus disease based upon findings from randomized trials [<a href="#rid62">62</a>], they consist of monoclonal antibodies against the surface glycoprotein of the <em>Zaire ebolavirus</em> and will not be effective against Marburg virus. (See  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease", section on 'Ebola-specific therapies'</a>.)</p><p>In the event of a new, large Marburg epidemic in Africa, it can be expected that there will be clinical trials of therapies for Marburg virus disease similar to the PALM trial for Ebola virus, which was conducted during the 2018-2019 Ebola epidemic in the Democratic Republic of the Congo [<a href="#rid62">62</a>]. </p><p>Possible experimental agents may include. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monoclonal antibodies</strong> – In 2015, a coalition of researchers isolated B cells from a Marburg survivor and created a panel of monoclonal antibodies (mabs), which they tested in laboratory animals [<a href="#rid63">63</a>]. A single dose of a mab designated MR191-N given four days postchallenge was able to prevent the death of guinea pigs infected with either the Ravn or Angola virus [<a href="#rid64">64</a>]. The same mab protected rhesus macaques when given in two doses on days 5 and 8 after an otherwise lethal challenge with either virus. Further development of these mabs produced MR186-YTE, a version of MR-191 modified to have an extended serum half-life [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nucleoside/nucleotide analogs</strong> – Several nucleos(t)ide analogs have demonstrated activity against Marburg virus:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The nucleoside analog prodrug favipiravir (T-705) was protective in mice and nonhuman primates infected with an otherwise lethal challenge dose of Marburg virus [<a href="#rid66">66,67</a>]. Favipiravir was assessed in patients with Ebola virus disease in West Africa but did not meet efficacy targets, and its use was discontinued.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The nucleotide analog <a class="drug drug_general" data-topicid="127259" href="/z/d/drug information/127259.html" rel="external">remdesivir</a> prevented the death of five of six cynomolgus macaques when given once daily for 12 days following an otherwise lethal challenge with the Angola strain of Marburg virus [<a href="#rid68">68</a>]. In addition, data suggest that there may be a role for combination therapy with remdesivir and mabs for the treatment of Marburg virus disease. Treatment of rhesus macaques infected with the Angola strain of Marburg virus with a combination of remdesivir and MR186-YTE gave better results than either treatment alone; all animals survived when therapy was initiated six days after virus challenge [<a href="#rid65">65</a>]. Remdesivir was evaluated for treatment of Ebola virus disease in the PALM trial in the DRC but was found to be less effective than mab therapies [<a href="#rid62">62</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The nucleoside analog BCX4430 (galidesivir), a potential broad-spectrum drug against RNA viruses [<a href="#rid69">69</a>], has been evaluated in animal studies for treatment of Marburg virus. It was efficacious in guinea pigs challenged with either the Ravn variant or the Musoke strain of the Lake Victoria variant of Marburg virus and also prevented the death of cynomolgus macaques when treatment began two days after challenge with the Musoke strain [<a href="#rid70">70</a>]. </p><p></p><p class="headingAnchor" id="H464353528"><span class="h1">VACCINE DEVELOPMENT</span><span class="headingEndMark"> — </span>There are no approved vaccines for the prevention of Marburg virus disease and those used to prevent Ebola virus disease will provide no benefit against Marburg. Until a vaccine is available, a strong public health response is key to controlling outbreaks of Marburg virus disease [<a href="#rid17">17,23,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease", section on 'Public health response'</a>.)</p><p>Efforts to develop Marburg vaccines are ongoing under the guidance of a World Health Organization-sponsored consortium (MARVAC) [<a href="#rid71">71</a>]. Candidate vaccines include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>VSV vaccines</strong> – In 2005, a single inoculation of a recombinant vesicular stomatitis virus (VSV) vaccine encoding the viral surface glycoprotein was shown to completely protect cynomolgus macaques against otherwise lethal challenge with the Musoke strain of Lake Victoria Marburg virus [<a href="#rid72">72</a>]. The following year, the same vaccine was found to provide postexposure protection when administered 24 or 48 hours after virus challenge [<a href="#rid73">73</a>]. </p><p></p><p class="bulletIndent1">Similar efficacy has been demonstrated against the Angola variant, using a vaccine encoding the Angola GP [<a href="#rid74">74-77</a>]. In one report, this vaccine resulted in complete protection of nonhuman primates challenged with the Angola strain [<a href="#rid78">78</a>]. A different study found that equal protection against the Angola strain could be achieved using a 1000-fold lower vaccine dose [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1">In 2020, a collaborative group subsequently developed a quadrivalent vaccine containing recombinant VSV encoding the surface glycoproteins of Marburg Angola, the<em> Zaire</em> and<em> Sudan</em> species of Ebola virus, and Lassa virus, and the vaccine protected cynomolgus macaques against challenge by each pathogen [<a href="#rid80">80</a>]. In early 2023, there was a new report of an experimental quadrivalent VSV vaccine containing an equal mixture of vaccines against the Zaire, Sudan, and Bundibugyo species of Ebola virus and the Angola variant of Marburg virus [<a href="#rid81">81</a>]. Cynomolgus macaques were given the quadrivalent vaccine and challenged seven days later with one of the four viruses. All animals except one challenged with the Zaire virus survived; by contrast, all control animals died.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenovirus/modified Vaccinia virus Ankara (MVA) vaccines</strong> – A multivalent antifilovirus vaccine encoding glycoproteins from Zaire Ebola virus, Sudan virus, Taï Forest virus, and Marburg virus has been developed. These glycoproteins are expressed by adenovirus serotypes 26 and 35 and MVA vectors. </p><p></p><p class="bulletIndent1">Cynomolgus macaques receiving the combination vaccine were protected against subsequent challenge by any of the four viruses [<a href="#rid82">82</a>]. In addition, phase I studies of the Ad26/MVA combination against Ebola and Marburg viruses in both adults and children have been conducted in Sierra Leone, and no safety concerns were identified [<a href="#rid83">83,84</a>]. </p><p></p><p class="bulletIndent1">More detailed information on adenovirus/MVA Ebola vaccines are presented separately. (See  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease", section on 'Ebola vaccines'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recombinant chimpanzee </strong><a class="drug drug_general" data-topicid="16483" href="/z/d/drug information/16483.html" rel="external">adenovirus vaccine</a> – A single injection of a replication-deficient recombinant chimpanzee adenovirus type 3 (chAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (chAd3-Marburg) was completely protective in nonhuman primates [<a href="#rid85">85</a>]. The same chAd3 vaccine was found to be safe and immunogenic in 40 healthy adults [<a href="#rid86">86</a>]. After a single vaccination, a glycoprotein-specific antibody response was detected in 95 and 70 percent of participants at 4 and 48 weeks, respectively. No serious adverse events related to vaccination occurred.</p><p></p><p>Future development might also include mRNA vaccines, given their success in the COVID-19 pandemic [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease", section on 'Ebola vaccines'</a> and  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p class="headingAnchor" id="H367109444"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113258.html" rel="external">"Society guideline links: Ebola virus"</a>.)</p><p class="headingAnchor" id="H1122730739"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The filoviruses are nonsegmented, negative-sense, single-stranded RNA viruses. The genus <em>Marburgvirus</em> contains a single species, which consists of two variants, <em>Lake Victoria marburgvirus</em> and <em>Ravn marburgvirus. </em>(See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The first recognized outbreak of Marburg virus disease occurred in Germany and Yugoslavia in 1967 as the result of the inadvertent importation of infected vervet monkeys from Uganda. Since then, all human infections have occurred in Africa, and fatality rates have been as high as 80 to 90 percent. Τhe largest epidemic, with some 250 confirmed cases, occurred in Angola in 2005. In 2023, outbreaks occurred in Equatorial Guinea and Tanzania. (See <a class="local">'Endemic areas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infectious Marburg virus has been recovered from cave-dwelling fruit bats in Uganda and in Sierra Leone, and viral RNA has been identified in bats in other parts of sub-Saharan Africa. Chronically infected animals shed virus in bodily fluids without becoming ill. (See <a class="local">'Viral reservoirs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial cases have resulted from contact with bats or from other unidentified exposures. Marburg virus disease then spreads from person to person through direct contact with the blood or other body fluids of a patient with Marburg virus disease or during preparation of a body for burial. (See <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After the virus enters the body via mucous membrane or skin penetration, macrophages and dendritic cells are the first cells to be infected. Filoviruses replicate readily within these cells, causing their necrosis and releasing large numbers of new viral particles into extracellular fluid  (<a class="graphic graphic_figure graphicRef57590" href="/z/d/graphic/57590.html" rel="external">figure 1</a>). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Marburg virus causes a rapidly progressive febrile illness that can lead to shock and death. Abnormalities in clinical laboratory tests include leukopenia, thrombocytopenia, elevations in serum transaminase (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) levels, increases in serum blood urea nitrogen (BUN) and creatinine, and abnormal coagulation indices. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of Marburg virus disease is based upon the detection of specific RNA sequences by reverse-transcription polymerase chain reaction (RT-PCR) or of viral antigens by enzyme-linked immunosorbent assay (ELISA). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient management is based primarily upon supportive care to limit tissue damage and prevent shock while the patient’s immune system mobilizes the responses needed to eliminate the infection. There are no approved therapies for Marburg virus disease. The monoclonal antibodies that are now in use to prevent or treat Ebola virus disease will provide no benefit against Marburg. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection prevention and control precautions used to care for patients with Marburg virus disease should be similar to those employed for patients with Ebola virus disease. These are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease", section on 'Infection control precautions during acute illness'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no approved vaccines for Marburg virus disease, and those used to prevent Ebola virus disease will provide no benefit against Marburg. Efforts to develop Marburg vaccines are ongoing; candidate vaccines include a recombinant vesicular stomatitis virus vaccine, a prime-boost strategy with a recombinant adenovirus followed by a recombinant <a class="drug drug_general" data-topicid="122670" href="/z/d/drug information/122670.html" rel="external">modified vaccinia Ankara vaccine</a>, and a recombinant chimpanzee <a class="drug drug_general" data-topicid="16483" href="/z/d/drug information/16483.html" rel="external">adenovirus vaccine</a>. (See <a class="local">'Vaccine development'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Bray M, Chertow D. Filoviruses. In: Clinical Virology, 4th, Richman DD, Whitley RJ, Hayden FG (Eds), ASM Press, 2017.</li><li><a class="nounderline abstract_t">Baseler L, Chertow DS, Johnson KM, et al. The Pathogenesis of Ebola Virus Disease. Annu Rev Pathol 2017; 12:387.</a></li><li><a class="nounderline abstract_t">Emanuel J, Marzi A, Feldmann H. Filoviruses: Ecology, Molecular Biology, and Evolution. Adv Virus Res 2018; 100:189.</a></li><li><a class="nounderline abstract_t">Negredo A, Palacios G, Vázquez-Morón S, et al. Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog 2011; 7:e1002304.</a></li><li><a class="nounderline abstract_t">Martini GA. Marburg virus disease. Postgrad Med J 1973; 49:542.</a></li><li><a class="nounderline abstract_t">Ristanović ES, Kokoškov NS, Crozier I, et al. A Forgotten Episode of Marburg Virus Disease: Belgrade, Yugoslavia, 1967. Microbiol Mol Biol Rev 2020; 84.</a></li><li><a class="nounderline abstract_t">Kortepeter MG, Dierberg K, Shenoy ES, et al. Marburg virus disease: A summary for clinicians. Int J Infect Dis 2020; 99:233.</a></li><li><a class="nounderline abstract_t">Koundouno FR, Kafetzopoulou LE, Faye M, et al. Detection of Marburg Virus Disease in Guinea. N Engl J Med 2022; 386:2528.</a></li><li class="breakAll">Marburg Virus Disease Outbreaks in Equatorial Guinea and Tanzania. Centers for Disease Control and Prevention. Available at: https://emergency.cdc.gov/han/2023/han00489.asp?ACSTrackingID=USCDC_511-DM102954&amp;ACSTrackingLabel=HAN%20489%20-%20General%20Public&amp;deliveryName=USCDC_511-DM102954. (Accessed on April 10, 2023).</li><li><a class="nounderline abstract_t">Glaze ER, Roy MJ, Dalrymple LW, Lanning LL. A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the 'Animal Rule'. Comp Med 2015; 65:241.</a></li><li><a class="nounderline abstract_t">Towner JS, Khristova ML, Sealy TK, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 2006; 80:6497.</a></li><li><a class="nounderline abstract_t">Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 2006; 355:909.</a></li><li><a class="nounderline abstract_t">Johnson ED, Johnson BK, Silverstein D, et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch Virol Suppl 1996; 11:101.</a></li><li><a class="nounderline abstract_t">Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006; 80:9659.</a></li><li><a class="nounderline abstract_t">Swenson DL, Warfield KL, Larsen T, et al. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008; 7:417.</a></li><li><a class="nounderline abstract_t">Towner JS, Amman BR, Sealy TK, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009; 5:e1000536.</a></li><li><a class="nounderline abstract_t">Adjemian J, Farnon EC, Tschioko F, et al. Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007. J Infect Dis 2011; 204 Suppl 3:S796.</a></li><li><a class="nounderline abstract_t">Gear JS, Cassel GA, Gear AJ, et al. Outbreake of Marburg virus disease in Johannesburg. Br Med J 1975; 4:489.</a></li><li><a class="nounderline abstract_t">Jeffs B, Roddy P, Weatherill D, et al. The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. I. Lessons learned in the hospital. J Infect Dis 2007; 196 Suppl 2:S154.</a></li><li><a class="nounderline abstract_t">Roddy P, Weatherill D, Jeffs B, et al. The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. II. lessons learned in the community. J Infect Dis 2007; 196 Suppl 2:S162.</a></li><li><a class="nounderline abstract_t">Timen A, Koopmans MP, Vossen AC, et al. Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis 2009; 15:1171.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Imported case of Marburg hemorrhagic fever - Colorado, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:1377.</a></li><li><a class="nounderline abstract_t">Knust B, Schafer IJ, Wamala J, et al. Multidistrict Outbreak of Marburg Virus Disease-Uganda, 2012. J Infect Dis 2015; 212 Suppl 2:S119.</a></li><li><a class="nounderline abstract_t">Nyakarahuka L, Shoemaker TR, Balinandi S, et al. Marburg virus disease outbreak in Kween District Uganda, 2017: Epidemiological and laboratory findings. PLoS Negl Trop Dis 2019; 13:e0007257.</a></li><li><a class="nounderline abstract_t">Wasswa H. Uganda grapples with new Marburg disease outbreak. BMJ 2017; 359:j5252.</a></li><li class="breakAll">World Health Organization. West Africa’s first-ever case of Marburg virus disease confirmed in Guinea. https://www.afro.who.int/news/west-africas-first-ever-case-marburg-virus-disease-confirmed-guinea (Accessed on August 25, 2021).</li><li><a class="nounderline abstract_t">Bonney JK, Adu B, Sanders T, et al. Marburg Virus Disease in Ghana. N Engl J Med 2023; 388:2393.</a></li><li class="breakAll">World Health Organization. Equatorial Guinea confirms first-ever Marburg virus disease outbreak. https://www.afro.who.int/countries/equatorial-guinea/news/equatorial-guinea-confirms-first-ever-marburg-virus-disease-outbreak (Accessed on February 21, 2023).</li><li><a class="nounderline abstract_t">Callaway E. Marburg virus outbreak: researchers race to test vaccines. Nature 2023; 614:603.</a></li><li class="breakAll">ProMed. Marburg Virus Disease-Equatorial Guinea. https://promedmail.org/promed-post/?id=8710134 (Accessed on May 26, 2023).</li><li class="breakAll">European Centre for Disease Prevention and Control. Weekly Bulletin: Communicable Disease Threats Report. Week 21, 21-27 May 2023. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Communicable%20disease%20threats%20report%2C%20May%202023%2C%20week%2021.pdf (Accessed on May 30, 2023).</li><li><a class="nounderline abstract_t">Samarasekera U. Marburg virus outbreak in Equatorial Guinea. Lancet Infect Dis 2023; 23:534.</a></li><li class="breakAll">World Health Organization. Marburg virus disease outbreak in Tanzania declared over. https://www.afro.who.int/countries/united-republic-of-tanzania/news/marburg-virus-disease-outbreak-tanzania-declared-over (Accessed on June 13, 2023).</li><li><a class="nounderline abstract_t">Amman BR, Jones ME, Sealy TK, et al. Oral shedding of Marburg virus in experimentally infected Egyptian fruit bats (Rousettus aegyptiacus). J Wildl Dis 2015; 51:113.</a></li><li><a class="nounderline abstract_t">Jones ME, Schuh AJ, Amman BR, et al. Experimental Inoculation of Egyptian Rousette Bats (Rousettus aegyptiacus) with Viruses of the Ebolavirus and Marburgvirus Genera. Viruses 2015; 7:3420.</a></li><li><a class="nounderline abstract_t">Amman BR, Carroll SA, Reed ZD, et al. Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog 2012; 8:e1002877.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Outbreak of Marburg virus hemorrhagic fever--Angola, October 1, 2004-March 29, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:308.</a></li><li><a class="nounderline abstract_t">Ogawa H, Miyamoto H, Nakayama E, et al. Seroepidemiological Prevalence of Multiple Species of Filoviruses in Fruit Bats (Eidolon helvum) Migrating in Africa. J Infect Dis 2015; 212 Suppl 2:S101.</a></li><li><a class="nounderline abstract_t">Pigott DM, Golding N, Mylne A, et al. Mapping the zoonotic niche of Marburg virus disease in Africa. Trans R Soc Trop Med Hyg 2015; 109:366.</a></li><li><a class="nounderline abstract_t">Amman BR, Bird BH, Bakarr IA, et al. Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa. Nat Commun 2020; 11:510.</a></li><li><a class="nounderline abstract_t">Pawęska JT, Storm N, Markotter W, et al. Shedding of Marburg Virus in Naturally Infected Egyptian Rousette Bats, South Africa, 2017. Emerg Infect Dis 2020; 26:3051.</a></li><li><a class="nounderline abstract_t">Kajihara M, Hang'ombe BM, Changula K, et al. Marburgvirus in Egyptian Fruit Bats, Zambia. Emerg Infect Dis 2019; 25:1577.</a></li><li><a class="nounderline abstract_t">Guito JC, Prescott JB, Arnold CE, et al. Asymptomatic Infection of Marburg Virus Reservoir Bats Is Explained by a Strategy of Immunoprotective Disease Tolerance. Curr Biol 2021; 31:257.</a></li><li><a class="nounderline abstract_t">Irving AT, Ahn M, Goh G, et al. Lessons from the host defences of bats, a unique viral reservoir. Nature 2021; 589:363.</a></li><li><a class="nounderline abstract_t">Nyakarahuka L, Schafer IJ, Balinandi S, et al. A retrospective cohort investigation of seroprevalence of Marburg virus and ebolaviruses in two different ecological zones in Uganda. BMC Infect Dis 2020; 20:461.</a></li><li><a class="nounderline abstract_t">Peters CJ. Marburg and Ebola--arming ourselves against the deadly filoviruses. N Engl J Med 2005; 352:2571.</a></li><li><a class="nounderline abstract_t">Coffin KM, Liu J, Warren TK, et al. Persistent Marburg Virus Infection in the Testes of Nonhuman Primate Survivors. Cell Host Microbe 2018; 24:405.</a></li><li><a class="nounderline abstract_t">Alves DA, Glynn AR, Steele KE, et al. Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques. Vet Pathol 2010; 47:831.</a></li><li><a class="nounderline abstract_t">Rougeron V, Feldmann H, Grard G, et al. Ebola and Marburg haemorrhagic fever. J Clin Virol 2015; 64:111.</a></li><li><a class="nounderline abstract_t">Lin KL, Twenhafel NA, Connor JH, et al. Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques. J Virol 2015; 89:9875.</a></li><li><a class="nounderline abstract_t">Basler CF. Molecular pathogenesis of viral hemorrhagic fever. Semin Immunopathol 2017; 39:551.</a></li><li><a class="nounderline abstract_t">Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol 2015; 13:663.</a></li><li><a class="nounderline abstract_t">Martines RB, Ng DL, Greer PW, et al. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 2015; 235:153.</a></li><li><a class="nounderline abstract_t">Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163:2371.</a></li><li><a class="nounderline abstract_t">Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618.</a></li><li><a class="nounderline abstract_t">Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179 Suppl 1:S177.</a></li><li><a class="nounderline abstract_t">Mahanty S, Hutchinson K, Agarwal S, et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003; 170:2797.</a></li><li><a class="nounderline abstract_t">Geisbert TW, Hensley LE, Gibb TR, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80:171.</a></li><li><a class="nounderline abstract_t">Bauer MP, Timen A, Vossen ACTM, van Dissel JT. Marburg haemorrhagic fever in returning travellers: an overview aimed at clinicians. Clin Microbiol Infect 2019; 21S:e28.</a></li><li><a class="nounderline abstract_t">Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011; 204 Suppl 3:S810.</a></li><li><a class="nounderline abstract_t">Broadhurst MJ, Kelly JD, Miller A, et al. ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet 2015; 386:867.</a></li><li><a class="nounderline abstract_t">Mulangu S, Dodd LE, Davey RT Jr, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med 2019; 381:2293.</a></li><li><a class="nounderline abstract_t">Flyak AI, Ilinykh PA, Murin CD, et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 2015; 160:893.</a></li><li><a class="nounderline abstract_t">Mire CE, Geisbert JB, Borisevich V, et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 2017; 9.</a></li><li><a class="nounderline abstract_t">Cross RW, Bornholdt ZA, Prasad AN, et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat Commun 2021; 12:1891.</a></li><li><a class="nounderline abstract_t">Zhu W, Zhang Z, He S, et al. Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model. Antiviral Res 2018; 151:39.</a></li><li><a class="nounderline abstract_t">Bixler SL, Bocan TM, Wells J, et al. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antiviral Res 2018; 151:97.</a></li><li><a class="nounderline abstract_t">Porter DP, Weidner JM, Gomba L, et al. Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus. J Infect Dis 2020; 222:1894.</a></li><li><a class="nounderline abstract_t">Julander JG, Demarest JF, Taylor R, et al. An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. Antiviral Res 2021; 195:105180.</a></li><li><a class="nounderline abstract_t">Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508:402.</a></li><li><a class="nounderline abstract_t">Cross RW, Longini IM, Becker S, et al. An introduction to the Marburg virus vaccine consortium, MARVAC. PLoS Pathog 2022; 18:e1010805.</a></li><li><a class="nounderline abstract_t">Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786.</a></li><li><a class="nounderline abstract_t">Daddario-DiCaprio KM, Geisbert TW, Ströher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399.</a></li><li><a class="nounderline abstract_t">Woolsey C, Geisbert JB, Matassov D, et al. Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. J Infect Dis 2018; 218:S582.</a></li><li><a class="nounderline abstract_t">Marzi A, Menicucci AR, Engelmann F, et al. Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation. Front Immunol 2018; 9:3071.</a></li><li><a class="nounderline abstract_t">Marzi A, Jankeel A, Menicucci AR, et al. Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease. Front Immunol 2021; 12:774026.</a></li><li><a class="nounderline abstract_t">Woolsey C, Cross RW, Agans KN, et al. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl Trop Dis 2022; 16:e0010433.</a></li><li><a class="nounderline abstract_t">Cooper CL, Morrow G, Yuan M, et al. Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials. Vaccines (Basel) 2022; 10.</a></li><li><a class="nounderline abstract_t">O'Donnell KL, Feldmann F, Kaza B, et al. Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine. EBioMedicine 2023; 89:104463.</a></li><li><a class="nounderline abstract_t">Cross RW, Xu R, Matassov D, et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J Clin Invest 2020; 130:539.</a></li><li><a class="nounderline abstract_t">Woolsey C, Borisevich V, Agans KN, et al. A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus. J Infect Dis 2023; 228:S660.</a></li><li><a class="nounderline abstract_t">Callendret B, Vellinga J, Wunderlich K, et al. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS One 2018; 13:e0192312.</a></li><li><a class="nounderline abstract_t">Milligan ID, Gibani MM, Sewell R, et al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA 2016; 315:1610.</a></li><li><a class="nounderline abstract_t">Afolabi MO, Ishola D, Manno D, et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis 2022; 22:110.</a></li><li><a class="nounderline abstract_t">Finch CL, King TH, Alfson KJ, et al. Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs. Vaccines (Basel) 2022; 10.</a></li><li><a class="nounderline abstract_t">Hamer MJ, Houser KV, Hofstetter AR, et al. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet 2023; 401:294.</a></li><li><a class="nounderline abstract_t">Meyer M, Huang E, Yuzhakov O, et al. Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease. J Infect Dis 2018; 217:451.</a></li></ol></div><div id="topicVersionRevision">Topic 98084 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bray M, Chertow D. Filoviruses. In: Clinical Virology, 4th, Richman DD, Whitley RJ, Hayden FG (Eds), ASM Press, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959626" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Pathogenesis of Ebola Virus Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29551136" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Filoviruses: Ecology, Molecular Biology, and Evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039362" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Discovery of an ebolavirus-like filovirus in europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4207635" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Marburg virus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32404328" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A Forgotten Episode of Marburg Virus Disease: Belgrade, Yugoslavia, 1967.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758690" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Marburg virus disease: A summary for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767445" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Detection of Marburg Virus Disease in Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767445" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Detection of Marburg Virus Disease in Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26141449" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the 'Animal Rule'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775337" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16943403" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Marburg hemorrhagic fever associated with multiple genetic lineages of virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800792" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16973570" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444889" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19649327" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Isolation of genetically diverse Marburg viruses from Egyptian fruit bats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21987753" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/811315" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Outbreake of Marburg virus disease in Johannesburg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940944" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. I. Lessons learned in the hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940945" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. II. lessons learned in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19751577" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Response to imported case of Marburg hemorrhagic fever, the Netherland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019654" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Imported case of Marburg hemorrhagic fever - Colorado, 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209681" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Multidistrict Outbreak of Marburg Virus Disease-Uganda, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30883555" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Marburg virus disease outbreak in Kween District Uganda, 2017: Epidemiological and laboratory findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133548" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Uganda grapples with new Marburg disease outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133548" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Uganda grapples with new Marburg disease outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37342928" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Marburg Virus Disease in Ghana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37342928" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Marburg Virus Disease in Ghana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36792905" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Marburg virus outbreak: researchers race to test vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36792905" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Marburg virus outbreak: researchers race to test vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36792905" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Marburg virus outbreak: researchers race to test vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37086728" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Marburg virus outbreak in Equatorial Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37086728" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Marburg virus outbreak in Equatorial Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25375951" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Oral shedding of Marburg virus in experimentally infected Egyptian fruit bats (Rousettus aegyptiacus).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26120867" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Experimental Inoculation of Egyptian Rousette Bats (Rousettus aegyptiacus) with Viruses of the Ebolavirus and Marburgvirus Genera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23055920" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800477" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outbreak of Marburg virus hemorrhagic fever--Angola, October 1, 2004-March 29, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25786916" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Seroepidemiological Prevalence of Multiple Species of Filoviruses in Fruit Bats (Eidolon helvum) Migrating in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25820266" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mapping the zoonotic niche of Marburg virus disease in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31980636" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33219802" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Shedding of Marburg Virus in Naturally Infected Egyptian Rousette Bats, South Africa, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31146800" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Marburgvirus in Egyptian Fruit Bats, Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33157026" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Asymptomatic Infection of Marburg Virus Reservoir Bats Is Explained by a Strategy of Immunoprotective Disease Tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33473223" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Lessons from the host defences of bats, a unique viral reservoir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32611400" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A retrospective cohort investigation of seroprevalence of Marburg virus and ebolaviruses in two different ecological zones in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972860" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Marburg and Ebola--arming ourselves against the deadly filoviruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30173956" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Persistent Marburg Virus Infection in the Testes of Nonhuman Primate Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807825" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25660265" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ebola and Marburg haemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26202230" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28555386" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Molecular pathogenesis of viral hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26439085" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25297522" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633609" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14639531" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988182" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12626527" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10701687" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24816494" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Marburg haemorrhagic fever in returning travellers: an overview aimed at clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21987756" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Basic clinical and laboratory features of filoviral hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26119838" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31774950" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25723164" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mechanism of human antibody-mediated neutralization of Marburg virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28381540" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33767178" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Combination therapy protects macaques against advanced Marburg virus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29369776" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29289666" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32479636" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551346" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590073" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36227853" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : An introduction to the Marburg virus vaccine consortium, MARVAC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15937495" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650649" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29939296" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30723475" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34777392" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35622847" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36298451" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36774693" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31820871" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37171813" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29462200" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27092831" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34529962" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36423030" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36709074" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29281112" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
